This dual cytoskeletal stabilization strategy mitigates activity-dependent synaptic loss and axonal transport deficits, key hallmarks of early AD, while disrupting the self-perpetuating cycle of tau mislocalization, oligomerization, and prion-like propagation. The gene discussed is MAPT; the disease is Alzheimer disease.